New GLP-1 Hair Loss Insights; Wegovy in Kids; Are Fitness Trackers Lying to Users?
[post_content]
Disclaimer: This article has been automatically aggregated from
Men predisposed to androgenetic alopecia had a higher risk of hair loss when using GLP-1 drugs, a Mendelian randomization study suggested. (Journal of Investigative Dermatology)
Truveta data indicated a 19% increase in GLP-1 prescribing among eligible beneficiaries after the Medicare GLP-1 Bridge program was launched.
The FDA said a supplement promoted and sold for weight loss (Lipofit Extreme Fat Burner 2.0) was recalled after an analysis showed tablets were tainted with undeclared fluoxetine and 2,4-dinitrophenol, a toxic substance used as a pesticide.
Amid ongoing shortages, the FDA said it’s working with manufacturers to boost the supply of estrogen patches.
The agency also expanded its list of safety concerns regarding unapproved GLP-1 formulations, including risks associated with multidose vials. (Becker’s Hospital Review)
In the phase III STEP Young trial, over 40% of children ages 6 to 11 years reversed their obesity status after 68 weeks of semaglutide (Wegovy), Novo Nordisk said.
The Defense Department temporarily rescinded clinical guidance for mandatory screening for testosterone deficiency in troops shortly after releasing it. (CBS News)
In female mice, late-life administration of semaglutide was tied to slowed biological aging indicators and extended lifespan. (Nature)
The Endocrine Society applauded the House introduction of the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, aimed at addressing insulin affordability.
A review on obesity-related obstructive sleep apnea suggested that GLP-1 receptor agonists may be best positioned as adjunctive therapy alongside continuous positive airway pressure and other therapies. (JAMA Otolaryngology–Head & Neck Surgery)
Smartwatches may significantly overestimate how many calories are burned during exercise, especially in people with higher body fat. (PLOS One)
The Department of Justice said it reached an agreement with Mount Sinai in New York in which the health system will no longer provide gender-affirming care for minors.
An online survey in Australia found that transgender and gender-diverse adults with autism had more difficulty adhering to gender-affirming hormone therapy. (Journal of Clinical Endocrinology & Metabolism)
for informational purposes only. We do not claim ownership, accuracy, or liability for the content provided. All rights belong to the original publisher.